Esperion Therapeutics Inc. ESPR

NAS: ESPR | ISIN: US29664W1053 14/11/2024

2,100 USD (-5,83%)

(-5,83%) 14/11/2024

Grafiek Esperion Therapeutics Inc.

Grafiek Esperion Therapeutics Inc.

1 dag1d -5,83%
1 week1w -7,89%
1 maand1m -1,41%
3 maanden3m 6,60%
6 maanden6m -8,70%
1 jaar1j 82,61%
5 jaar5j -94,81%

Esperion Therapeutics Inc. in het nieuws

Toon enkel gratis nieuws

26 september 2023 · Thinking about buying stock in Pliant Therapeutics, Esperion Therapeutics, Murphy Canyon Acquisition Corp, Limbach Holdings, or Vaccitech? · Persbericht

17 maart 2021 · NEXLETOL® (bempedoic acid) Tablet, ezetimibe and atorvastatin combination lowered bad cholesterol by 60.5% vs. placebo in Phase 2 study · Persbericht

23 februari 2021 · ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update · Persbericht

29 januari 2021 · Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

13 januari 2021 · ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program · Persbericht

Profiel Esperion Therapeutics Inc.

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.esperion.com

Hoofdzetel: Ann Arbor, Michigan Verenigde Staten

CEO: Timothy Mayleben

Werknemers: 160

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe